ERBB2 and adenocarcinoma: It was observed that 79.1% (72/91) of the cases with amplification were IT according to the LC, and the frequency of HER2 amplification was found to be statistically significantly higher in intestinal-type adenocarcinomas (P < .000) (Figure 4E).